BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Feb. 21, 2007
View Archived Issues
Shire Buying Vyvanse Partner New River For $64 Per Share
Shire plc, which partnered with New River Pharmaceuticals Inc. two years on a drug for attention deficit hyperactivity disorder, agreed to acquire the smaller firm for $2.6 billion in cash. (BioWorld Today)
Read More
Lux Starts Phase III Studies; Isotechnika Raises $34.5M
Read More
New Autism Clues As Prevalence Estimates Increase Once Again
Read More
Caprion, Ecopia Merger Gets $45M Pledge From Investors
Read More
Theratechnologies Bringing In C$52.5M To Fund Phase III Trial
Read More
BioMarin Pharma Misses With Phase IIa Hypertension Trial
Read More
Other News To Note
Read More
Clinic Roundup
Read More